Multiple myeloma is the second most common blood cancer in the United States, and it is more common in men, with an estimated 20,030 new male cases diagnosed in 2025. Multiple myeloma is the ...

In June 2025, we reported on a study that showed long-term survival with undetectable disease in heavily pretreated multiple myeloma. The results not only added fresh evidence of efficacy for CAR ...

In a phase 1–2 trial, teclistamab, a bispecific antibody targeting CD3 on T-cell surfaces and B-cell maturation antigen on myeloma cells, showed durable responses in heavily pretreated patients with ...

How to Train Your Dragon is a beloved animated franchise that has recently spawned the live-action film starring Mason Thames, Niko Parker and Gerard Butler. The 2025 film has grossed over $636 ...

For the first time, patients with abnormal cells detected in their bone marrow have a treatment option before the condition develops into multiple myeloma. The FDA has approved Johnson & Johnson’s ...

Stage 1 multiple myeloma features low beta-2 microglobulin, high albumin, and no organ damage, often detected incidentally. Diagnosis involves blood, urine, imaging tests, and bone marrow biopsy to ...

Histopathological image of multiple myoloma. Smear preparation of bone marrow aspirate stained with May-Grünwald-Giemsa procedure. It doest not represent a histopathologic image but essentially helps ...

The stablecoin-focused Plasma blockchain's native token, XPL, debuted on major exchanges, including Binance and OKX, on Thursday. The token drew a price of up to $1.54 in early trading, resulting in a ...

Multiple myeloma is a chronic (long-term) blood cancer that affects plasma cells made in the bone marrow, which is spongy tissue found inside bones. While people with multiple myeloma can live for ...

Multiple myeloma is a form of blood cancer you may never have heard of–and that makes sense, because it’s, thankfully, pretty rare. That said, if you’re one of the unlucky few (your average lifetime ...

Panelists highlight advances in myeloma treatment, focusing on innovative T cell therapies like CAR T and T cell engagers, along with potent new CELMoD drugs, all offering more targeted and effective ...